Mozavaptan
Jump to navigation
Jump to search
Template:Short description Template:Drugbox
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- Script error: No such module "Citation/CS1".
- Script error: No such module "citation/CS1".
Template:Diuretics
Template:Oxytocin and vasopressin receptor modulators